An Introduction to Idiopathic Pulmonary Fibrosis

The agency estimates that limiting nicotine levels could lead to 1.8 million fewer tobacco-related deaths by 2060 and health care savings of $1.1 trillion a year over the next 40 years.

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

The FDA approved the addition of Guillain-Barré syndrome warnings for Abrysvo and Arexvy, citing postmarketing data suggesting an increased risk.

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

Your daily dose of the clinical news you may have missed.

A woman in her mid-50s arrives at the ED for suspected anaphylaxis; SOB has not responded to epinephrine and steroids. Does the CT scan suggest a Dx?